Characteristics of patients with undiagnosed stage 3 chronic kidney disease: results from an observational study (REVEAL-CKD) in China
The Lancet Regional Health - Western Pacific · 2025-01 · 54 · 101275
DOI: 10.1016/j.lanwpc.2024.101275 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Regional Health - Western Pacific, 2025-01. Verfasst von Sheng Nie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, National Clinical Research Centre for Kidney Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, South…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Early diagnosis of chronic kidney disease (CKD) is crucial for timely intervention to delay disease progression and improve patient outcomes. However, data for clinical characteristics of Chinese patients with undiagnosed, early-stage CKD are lacking.
Methods
REVEAL-CKD is a multinational, observational study using real-world data in selected countries to describe factors associated with undiagnosed stage 3 CKD, time to diagnosis, and CKD management post diagnosis. We analysed patient data from 20 hospitals in the China Renal Data System. Adult patients with two consecutive estimated glomerular filtration rate (eGFR) measurements indicating stage 3 CKD (30- 90-730 days apart from 2015 to 2020 were eligible.
Findings
Among 35,222 eligible patients, 25,214 (71.6%) were undiagnosed (lacked a CKD diagnostic code before and up to six months post-second-qualifying-eGFR). Only 2344 (9.3%) undiagnosed patients eventually received a delayed diagnosis, whose median time to diagnosis was 18.1 (95% CI: 17.6-18.8) months. Age ≥65 years, being female, stage 3A CKD, and the absence of nephrology visit and comorbidities (diabetes, established cardiovascular disease, heart failure, hypertension, or chronic nephritic syndrome) were associated with undiagnosed CKD (P < 0.001). Among the diagnosed patients, the proportion receiving ≥1 prescription of guideline-recommended medications (e.g. renin-angiotensin system inhibitors) increased and their eGFR decline attenuated post-diagnosis.
Interpretation
The high proportion of undiagnosed, early-stage CKD, and delayed diagnosis are concerning. The improved prescription patterns and the attenuation of eGFR decline post-diagnosis demonstrate the importance of early diagnosis and timely intervention in CKD patients. Funding: AstraZeneca China.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, National Clinical Research Centre for Kidney Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Real World Science and Analytics, Evidence, BioPharmaceutical Medical, AstraZeneca, Mölndal, Sweden.
- Medical Affairs CVRM, AstraZeneca Pharmaceutical (Hangzhou) Co. Ltd. Company, Hangzhou, China.
- Biometrics and RWE, Evidence Generation, AstraZeneca Investment (CN) Co Ltd, Shanghai, China.
- Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Zitieren
APA
Nie, S., Zhou, S., Cabrera, C., Chen, S., Jia, M., Zhang, S., Su, L., Gao, Q., Tangri, N., & Hou, F. F. (2025). Characteristics of patients with undiagnosed stage 3 chronic kidney disease: results from an observational study (REVEAL-CKD) in China. The Lancet Regional Health - Western Pacific, 54, 101275. https://doi.org/10.1016/j.lanwpc.2024.101275
Vancouver
Nie S, Zhou S, Cabrera C, Chen S, Jia M, Zhang S, et al. Characteristics of patients with undiagnosed stage 3 chronic kidney disease: results from an observational study (REVEAL-CKD) in China. The Lancet Regional Health - Western Pacific. 2025;54:101275. doi:10.1016/j.lanwpc.2024.101275
BibTeX
@article{Nie2025,
author = {Nie, Sheng and Zhou, Shiyu and Cabrera, Claudia and Chen, Shan and Jia, Mengyun and Zhang, Shiyu and Su, Licong and Gao, Qi and Tangri, Navdeep and Hou, Fan Fan},
title = {Characteristics of patients with undiagnosed stage 3 chronic kidney disease: results from an observational study (REVEAL-CKD) in China},
journal = {The Lancet Regional Health - Western Pacific},
year = {2025},
volume = {54},
pages = {101275},
doi = {10.1016/j.lanwpc.2024.101275}
}
EUVIMED